My ePortfolio Register   

EMUC17 highlights: Prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.11.17
Views: 1547

Dr Jan Oldenburg - University of Oslo, Oslo, Norway and Mr Simon Brewster - Oxford University Hospitals, Oxford, UK

Dr Jan Oldernburg and Mr Simon Brewster discuss their highlights from EMUC17 focusing on prostate cancer and presented posters from the conference.

They discuss a prize-winning poster that looked into the management of patients with non-metastatic prostate cancer who were randomised in to three treatment groups. The poster illustrated interesting data about how performance status and high-risk disease confer increased risk of prostate cancer death.

The experts also discuss the use of genetic testing and biomarkers in the treatment of patients with prostate cancer, highlighting data from the ENGRAIL 2 trial and studies into the use of AR V-7 as a molecular prognostic marker.

Future treatments including PARP inhibitors and the TRITON studies as well as radical radiotherapy in oligometastatic disease are discussed as interesting therapeutics for the future clinical management of patients with prostate cancer.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence